Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon‐alpha 2a plus ribavirin

Background  Individualized treatment regimens, taking into account the heterogeneity of patients with chronic hepatitis C, are needed to improve treatment outcomes.

[1]  G. Davis.  Tailoring antiviral therapy in hepatitis C , 2006, Hepatology.

[2]  P. Marcellin,et al.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy , 2006, Hepatology.

[3]  Nikolai V Naoumov,et al.  Individualization of antiviral treatment regimens for chronic hepatitis C , 2006, European journal of gastroenterology & hepatology.

[4]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[5]  R. Bartenschlager,et al.  The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. , 2006, Journal of hepatology.

[6]  Roger Williams,et al.  Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. , 2005, Journal of hepatology.

[7]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[8]  Limin Chen,et al.  Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. , 2005, Gastroenterology.

[9]  G. Drusano,et al.  A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. , 2004, The Journal of infectious diseases.

[10]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[11]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[12]  A. Perelson,et al.  Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin , 2003, Hepatology.

[13]  E. Herrmann,et al.  Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon , 2003, Hepatology.

[14]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[15]  A. Andriulli,et al.  High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. , 2002, Journal of hepatology.

[16]  Marilyn M. Wagener,et al.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .

[17]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[18]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[19]  P. Simmonds,et al.  Genotype Dependence of Hepatitis C Virus Load Measurement in Commercially Available Quantitative Assays , 1999, Journal of Clinical Microbiology.

[20]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[21]  M. Buti,et al.  Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.

[22]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[23]  T. Poynard.  Treatment of Hepatitis C Virus: The First Decade , 2004, Seminars in liver disease.

[24]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[25]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[26]  G. Alexander,et al.  Relationship Between Expression of Hepatitis B Virus Antigens in Isolated Hepatocytes and Autologous Lymphocyte Cytotoxicity in Patients with Chronic Hepatitis B Virus Infection , 1984, Hepatology.